SCHEMBL2913196

SCHEMBL2913196

Cc1cc(O[Si](C)(C)C(C)(C)C)cc(C)c1-c1cccc(COc2ccc(C=O)cc2)c1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 2/20 0.44
▸ CD274 Q9NZQ7 8/20 0.38
▸ CCNB2 O95067 1/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ CCNB1 P14635 1/20 0.36
▸ CCND1 P24385 1/20 0.36
▸ CCNB3 Q8WWL7 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ MAPT P10636 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12578115 0.90 FFAR1 (0.40) FFAR1CD274CCNB2CDK1CDK4
SCHEMBL2022943 0.89 CD274 (0.38) FFAR1CD274ALDH1A1KDM4E
SCHEMBL13117640 0.89 CD274 (0.44) FFAR1CD274ALDH1A1SMN1; SMN2RAB9A
SCHEMBL12577734 0.88 FFAR1 (0.38) FFAR1CD274CCNB2CDK1CDK4
SCHEMBL2907411 0.84 FFAR1 (0.41) FFAR1CD274ALDH1A1MAPT
SCHEMBL13117643 0.84 FFAR1 (0.40) FFAR1CD274CCNB2CDK1CDK4
SCHEMBL2986192 0.84 FFAR1 (0.38) FFAR1CD274CCNB2CDK1CDK4
SCHEMBL12577697 0.83 CD274 (0.44) CD274ALDH1A1SMN1; SMN2RAB9AMAPT
SCHEMBL2912263 0.82 FFAR1 (0.54) FFAR1CD274CCNB2CDK1CDK4
SCHEMBL12578021 0.82 FFAR1 (0.61) FFAR1CD274CCNB2CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-10-21 — — US disclosed
EP-2216330-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2010-08-11 — — EP disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 FFAR1 64/4885CD274 2600/4885CCNB2 4780/4885
US-20100267775-A1 OXADIAZOLIDINEDIONE COMPOUND GPR119, GLP1R, GPR4 FFAR1 38/4885CD274 1333/4885CCNB2 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback